However, promising results have been obtained in clinical trials with CAR T cells targeting BCMA, HDAC inhibitors, and oncolytic reovirus, supporting the relevance of these alternative strategies in the treatment of MM. Here, TNFRSF17 is linked to Miyoshi myopathy.